Unerwünschte pulmonale Arzneimittelwirkungen

D. Mazur; R. Stahlmann

doi:10.1055/s-2008-1017479

DMW - Deutsche Medizinische Wochenschrift, Inhaltsverzeichnis

Dtsch Med Wochenschr 2008; 133(3): 81-86
DOI: 10.1055/s-2008-1017479

Aktuelle Diagnostik & Therapie | Review article

Pneumologie, Pharmakologie
© Georg Thieme Verlag KG Stuttgart · New York

Unerwünschte pulmonale Arzneimittelwirkungen

Drug-induced adverse pulmonary reactionsD. Mazur¹ , R. Stahlmann¹

¹Institut für Klinische Pharmakologie und Toxikologie, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin

Abstract

Schlüsselwörter

Nebenwirkungen - Lunge - Fibrose

Key words

side effects - lung - fibrosis

Volltext

Referenzen

Literatur

1 Angle P, Thomas P, Chiu B, Freedman J. Bronchiolitis obliterans with organizing pneumonia and cold agglutinin disease associated with phenytoin hypersensitivity syndrome. Chest. 1997; 112 1697-1699
2 Azzam I, Tov N, Elias N, Naschitz J E. Amiodarone toxicity presenting as pulmonary mass and peripheral neuropathy: the continuing diagnostic challenge. Postgrad Med. 2006; 82 73-75
3 Aronchik J M, Gefter W B. Drug-induced pulmonary disease: An update. J Thorac Imaging. 1991; 6 19-29
4 Bryant D H. Drug-induced pulmonary disease. Med J Austr. 1992; 156 802-805
5 Camus P, Martin W J, Rosenow E C. Amiodarone pulmonary toxicity. Clin Chest Med. 2004; 25 65-75
6 Clayton B D, Hitchcock M G, Williford P M. Minocycline hypersensitivity with respiratory failure. Arch Dermatol. 1999; 135 139-140
7 Cooper J AD, White D A, Matthay R A. Drug-induced pulmonary disease. Part 2: noncytotoxic drugs. Am Rev Respir Disease. 1986; 133 488-505
8 Cooper J AD, Zitnik R J, Matthay R A. Mechanisms of drug-induced pulmonary disease. Ann Rev Med. 1988; 39 395-404
9 Filipek W J. Drug-induced pulmonary disease. Postgrad Med. 179; 65 131-140
10 Foucher P, Biour M, Blayac J P. et al . Drugs that may injure the respiratory system. Eur Respir J. 1997; 10 265-279
11 Grahmann P, Kroegel C. Pulmonale Arzneimittel-Nebenwirkungen. Arzneimitteltherapie. 2000; 11 337-349
12 Hayes D, Anstead M I, Kuhn R J. Eosinophilic pneumonia induced by daptomycin. J Infection. 2007; 54 e211-e213
13 Huggins J T, Sahn S A. Drug-induced pleural disease. Clin Chest Med. 2004; 25 141-153
14 Jarand J, Lee A, Leigh R. Amiodaronoma: an unusual form of amiodarone-induced pulmonary toxicity. Practice. 2007; 176 1411-1443
15 Lunde H, Hedner T, Samuelsson O. et al . Dyspnoea, asthma and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ. 1994; 308 18-21
16 Mendez J L, Nadrous H F, Hartman T E, Ryu J H. Chronic nitrofurantoin-induced lung disease. Mayo Clini Proc. 2005; 80 1298-1302
17 Ott M C, Khoor, Leventhal J P, Paterick T E, Burger C D. Pulmonary toxicity in patients receiving low-dose amiodaron. Chest. 2003; 123 646-651
18 Polman A J, van der Werf T S, Tiebosch A TMC, Zijlstra J G. Early-onset phenytoin toxicity mimicking a renopulmonary syndrome. Eur Respir J. 1998; 11 501-503
19 Rosenow E C, Limper A H. Drug-induced pulmonary disease. Semin Respir Infect. 1995; 10 86-95
20 Rosenow E C, Myers J L, Swensen S J, Pisani R J. Drug-induced pulmonary disease - an update. Chest. 1992; 102 239-250
21 Sica D A, Brath L. Angiotensin-converting enzyme inhibition - emerging pulmonary issues relating to cough. Congestive Heart Failure. 2006; 07 - 08 223-226
22 Solomon J, Schwarz M. Drug-, toxin-, and radiation therapy-induced eosinophilic pneumonia. Semin Respir Crit Care Med. 2006; 27 192-198

Prof. Dr. med. Ralf Stahlmann,

Institut für Klinische Pharmakologie und Toxikologie

Garystr. 5

14195 Berlin

Telefon: 030/8445-1770

Fax: 030/8445-1763

eMail: ralf.stahlmann@charite.de